There is a gap between research, and the implementation of that research into usable outcomes in the marketplace, according to the Australian Private Equity and Venture Capital Association (AVCAL).
In its submission to the Senate inquiry on Australia's Innovation system last week, AVCAL called for a new national innovation policy.
"We know what we have to do, but unfortunately we've continued to ignore the ‘development' side of ‘research and development'," AVCAL chief Yasser El-Ansary said.
"We have to recognise that supportive innovation policy systems play a critical role in taking research from the laboratory to the marketplace, and this is particularly true for small and medium-sized economies like ours."
AVCAL's key recommendations include introducing a $500 million translational innovation fund to bring in matching private capital into high-risk but high-potential early stage companies, and a translational medical innovation fund funded from 10 per cent of the proposed $1 billion endowment of the Medical Research Future Fund.
It also wants an improvement in migration policies to strengthen innovation, introduction of quarterly research and development tax credits for early stage companies, and a strengthening of the nexus between publicly-funded research and economic outcomes.
Taking a purely passive investment approach is leaving many investors at risk of heightened valuation risks, Allan Gray and Orbis Investments have cautioned.
Annual trimmed mean inflation saw a slight spike in April, according to data from the ABS.
Active managers say that today’s market volatility and dislocation are creating a fertile ground for selective stock picking, reinforcing their case against so-called “closet indexers”.
Platform leaders admit they’re operating under constant pressure and a persistent “state of paranoia” to keep pace with technology that is reshaping how clients access and interact with their wealth.